AI주식인사이트AI Stock Insight
C

셀리드

299660KOSDAQ자연과학 및 공학 연구개발업

45.0 / 100

Reference Date: 2026-06-10

Financial Score20.5 / 40
News Sentiment12.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Plunged 19.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Cellid is a biopharmaceutical company with proprietary technologies CeliVax (cancer immunotherapy vaccine) and Ad5/35 (infectious disease prevention vaccine), developing six cancer immunotherapy vaccines including BVAC-C and BVAC-E6E7, as well as a COVID-19 vaccine. It is currently conducting Phase 1/2a and 3 clinical trials, and generates revenue through CMO/CDMO services and e-commerce sales, though no products are currently on the market.

Number of Employees

49people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
0.99Industry Average 3.247.0Point

Half of industry avg (excellent)

ROE
-19.25Industry Average -32.093.5Point

Below industry avg

Debt Ratio
9.75Industry Average 7.312.0Point

Higher than industry avg (caution)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲112.3% (1-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲3.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -27.6% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 2,490Won52-week high 7,39052-week low 2,315
1-month return0.0Point

1m -19.94% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-05-22
  • Neutral임시주주총회결과2026-05-22
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-20
  • Neutral분기보고서 (2026.03)2026-05-15